ReviewDiabetic medicine : a journal of the British Diabetic Association2025
Exploring the potential role of C-peptide in type 2 diabetes management.
Review in Diabetic medicine : a journal of the British Diabetic Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.Diabetes, obesity & metabolism · 2026Trial
- Validation of the ST1RE risk engine in Chinese with type 1 diabetes and comparison with the JADE, RECODe, and UKPDS risk scores.Journal of diabetes investigation · 2026Article
- Endogenous Recovery of Fasting C-Peptide Decreases Progression of Sudomotor Small-Fibre Dysfunction in Adults With Diabetes: A Real-World Cohort Study.Diabetes/metabolism research and reviews · 2026Article
- Baseline β-Cell Secretory Reserve and Its Association with Glycaemic Control and Long-Term Outcomes Across Diabetes Phenotypes.International journal of molecular sciences · 2026Article
- The evolution of C-peptide's role in diabetes care.Current opinion in endocrinology, diabetes, and obesity · 2026Review
- Peripheral Immune Reprogramming Characterizes a Low C-Peptide Subgroup of Type 2 Diabetes: Transcriptomic Profiling of Peripheral Blood Mononuclear Cells and Systemic Inflammation.Journal of inflammation research · 2026Article
- Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.Frontiers in endocrinology · 2026Review
- Correlation between C-peptide and diabetic retinopathy in patients with type 2 diabetes mellitus: a cross-sectional study.Scientific reports · 2025Article
- Exploring the potential role of C-peptide in type 2 diabetes management.Diabetic medicine : a journal of the British Diabetic Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Type 2 diabetes (T2D) is a complex condition characterised by the interaction between insulin resistance and beta cell dysfunction. C-peptide, a key biomarker of endogenous insulin secretion, has a role in diagnosing type 1 diabetes (T1D). However, its utility in T2D has not been extensively studied. This review provides an overview of the progression of C-peptide levels over time in T2D and discuss its interpretation in clinical settings. We reviewed current evidence on the relationship between C-peptide levels and response to antidiabetic drugs, as well as the utility of C-peptide testing in T2D treatment strategies. We also reviewed available evidence for C-peptide in predicting future outcomes in T2D. In this review, we hoped to clarify the value of C-peptide testing in understanding and managing T2D and to highlight areas where further research is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.